Predictors of SARS-CoV-2 anti-spike IgG antibody levels following two COVID-19 vaccine doses among children and adults in the Canadian CHILD Cohort
Predictors of SARS-CoV-2 anti-spike IgG antibody levels following two COVID-19 vaccine doses among children and adults in the Canadian CHILD Cohort
Simple item page
Full item details
- dc.contributor.author
- Azeez, Rilwan
- Lotoski, Larisa
- Winsor, Geoffrey L.
- Arnold, Corey R.
- Galipeau, Yannick
- Pelchat, Martin
- Goguen, Stephanie
- Simons, Elinor
- Moraes, Theo J.
- Mandhane, Piush J.
- Turvey, Stuart E.
- Bolotin, Shelly
- Patrick, David M.
- Bullard, Jared
- Lix, Lisa M.
- Doucas, Natasha
- Rodriguez, Natalie
- Brinkman, Fiona S. L.
- Subbarao, Padmaja
- Langlois, Marc-André
- Azad, Meghan B.
- dc.date.accessioned
- 2025-02-03T16:44:42Z
- dc.date.available
- 2025-02-03T16:44:42Z
- dc.date.issued
- 2023-09-08
- dc.description.abstract - en
- <p>Background Vaccination helps prevent SARS-CoV-2 infection and severe COVID-19. However, vaccine-induced humoral immune responses vary among individuals and wane over time. We aimed to describe the SARS-CoV-2 anti-spike IgG antibody response to vaccination and identify health and demographic factors associated with this response among children and adults.</p> <p>Methods We studied a subset of double-vaccinated children (n= 151; mean age: 12 ±1.5 years, 46% female) and adults (n= 995; 44 ±6.0 years, 60% female) from the Canadian CHILD Cohort. Dried blood spots were collected over two time periods (March 2021 to September 2021; October 2021 to January 2022). Antibody levels were quantified using automated chemiluminescent ELISAs. Demographic, vaccination, and health data were collected via online questionnaires. Associations were determined using multivariable regression.</p> <p>Results Our cohort had SARS-CoV-2 anti-spike seropositivity rate of 97% following two COVID-19 vaccine doses. In both children and adults, the highest antibody levels were observed around three months post-vaccination and did not differ by biological sex. Higher antibody levels were associated with: prior SARS-CoV-2 infection (β=0.15 scaled luminescence units, 95%CI, 0.06-0.24), age <18 years (β=0.15, 95%CI 0.05-0.26) and receiving the Moderna mRNA (β=0.23, 95%CI 0.11-0.34) or Pfizer-BioNTech mRNA vaccines (β= 0.10, 95%CI, 0.02-0.18) vs. a combination of mRNA and Oxford-AstraZeneca viral vector vaccines. There were no differences in antibody levels when comparing a 3-8 vs. 9-16-week interval between vaccine doses.</p> <p>Interpretation We identified key factors associated with post-vaccination antibody responses in children and adults, which could help improve future vaccine development and deployment among different population subgroups.</p>
- dc.description.sponsorship
- This work was supported by funding from the Canadian Institutes of Health Research and the Canadian COVID-19 Immunity Task Force (VR5-172658) and Research Manitoba (4494). Core funding for the CHILD Cohort Study was provided by the Canadian Institutes of Health Research [CIHR; AEC-85761, PJT-148484, FDN-159935, and EC1-144621], the Allergy, Genes and Environment Network of Centres of Excellence (AllerGen NCE) (12CHILD), BC Children Hospital Foundation, Don & Debbie Morrison, and Genome Canada/Genome BC (274CHI). This research was supported, in part, by the Canada Research Chairs program: MBA holds a Tier 2 Canada Research Chair in the Developmental Origins of Health and Disease; SET holds a Tier 1 Canada Research Chair in Pediatric Precision Health; PS holds Tier 1 Canada Research Chair in Pediatric Asthma & Lung Health EC is supported by a Social Science and Humanities Research Council Postdoctoral Fellowship. FSLB is an SFU Distinguished Professor. YG is supported by a Frederick Banting and Charles Best CGS-D from the Canadian Institutes of Health Research (476885). Production of COVID-19 reagents was financially supported by NRC's Pandemic Response Challenge Program.
- dc.identifier.doi
- https://doi.org/10.1101/2023.09.06.23294696
- dc.identifier.uri
- https://open-science.canada.ca/handle/123456789/3390
- dc.language.iso
- en
- dc.publisher - en
- medRxiv
- dc.rights - en
- Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
- dc.rights - fr
- Creative Commons Attribution - Pas d'utilisation commerciale - Pas de modification 4.0 International (CC BY-NC-ND 4.0)
- dc.rights.uri - en
- https://creativecommons.org/licenses/by-nc-nd/4.0/
- dc.rights.uri - fr
- https://creativecommons.org/licenses/by-nc-nd/4.0/deed.fr
- dc.subject - en
- Health
- Coronavirus diseases
- Immunization
- dc.subject - fr
- Santé
- Maladie à coronavirus
- Immunisation
- dc.subject.en - en
- Health
- Coronavirus diseases
- Immunization
- dc.subject.fr - fr
- Santé
- Maladie à coronavirus
- Immunisation
- dc.title - en
- Predictors of SARS-CoV-2 anti-spike IgG antibody levels following two COVID-19 vaccine doses among children and adults in the Canadian CHILD Cohort
- dc.type - en
- Submitted manuscript
- dc.type - fr
- Manuscrit soumis
- local.pagination
- 1-23
- local.peerreview - en
- No
- local.peerreview - fr
- Non
Download(s)
Original bundle
1 - 1 of 1
Name: azeez-predictors-sars-cov-2-anti-spike-IgG-antibody-levels-covid-19-vaccine-doses.pdf
Size: 1.49 MB
Format: PDF
Collection(s)